Amit Bahl is Consultant Clinical Oncologist with a special interest in breast and urological cancers at Bristol Cancer Institute, University Hospitals Bristol, Bristol, UK. He is also Clinical Director at the Genesis Care Centre in Bristol and Director of Oncology at Spire Healthcare, UK. Prof. Bahl is the Research Lead for Uro-oncology at Bristol Haematology and Oncology Centre and has led and developed the prostate brachytherapy service in Bristol. He has also been an expert adviser to the National Institute for Health and Care Excellence (NICE) for technology appraisals on new drugs and an external service reviewer at oncology departments across the UK.
Prior to his current roles, Prof. Bahl became Member of the Royal College of Physicians (RCP) and trained in Clinical Oncology, achieving Fellowships of the RCP and of the Royal College of Radiologists (RCR). He has also been a member of the National Cancer Research Institute (NCRI) Clinical Studies Group for renal, bladder, and prostate cancer, and is a current member of the NCRI Clinical Studies Group for penile cancer. He has been a college tutor of the RCR for 10 years, supervising several MD theses in breast and prostate cancer research, and he is an Executive Committee member of the British Uro-oncology Group (BUG).
Prof. Bahl is actively involved in research into breast, prostate, bladder, and penile cancers and has more than 100 publications and has given several presentations at national and international meetings in these research areas. In 2012, Prof. Bahl was awarded the Cochrane Shanks-Jalil Travelling Professorship by the RCR, and he is a Visiting Professor at two international centres and at the University of the West of England in Bristol. He currently holds research grants in excess of GBP 3 million and is Chief Investigator for several multicentre trials focused on new modalities of treatment for breast and prostate cancer. He is also leading a robotic brachytherapy project.
EM-39651 - Date of preparation: August 2020